Technical Analysis for KROS - Keros Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 55.26 | 2.07% | 1.12 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Flat | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 2.07% | |
| Oversold Stochastic | Weakness | 2.07% | |
| 200 DMA Resistance | Bearish | 3.06% | |
| MACD Bearish Centerline Cross | Bearish | 3.06% | |
| Doji - Bullish? | Reversal | 3.06% | |
| Down 3 Days in a Row | Weakness | 3.06% | |
| Down 4 Days in a Row | Weakness | 3.06% | |
| Down 5 Days in a Row | Weakness | 3.06% | |
| Oversold Stochastic | Weakness | 3.06% | |
| Fell Below 200 DMA | Bearish | 2.31% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakout | 31 minutes ago |
| Rose Above Previous Day's High | 31 minutes ago |
| Up 1% | 31 minutes ago |
| 60 Minute Opening Range Breakdown | about 2 hours ago |
| Down 1% | about 2 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 11/04/2024
Keros Therapeutics, Inc. Description
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or FOP, and is currently in a Phase 1 clinical trial; and KER-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or PAH. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Organ Systems Bone Rare Diseases Disorders Hypertension Therapeutic Products Hematology Anemia Pulmonary Arterial Hypertension Myelodysplastic Syndrome Osteoporosis Syndromes Genodermatoses Skeletal Disorders Bone Disease Molecule Product Thrombocytopenia Myelofibrosis Hematopathology Musculoskeletal Disorders Osteogenesis Imperfecta
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 73.0 |
| 52 Week Low | 27.31 |
| Average Volume | 376,662 |
| 200-Day Moving Average | 55.43 |
| 50-Day Moving Average | 59.38 |
| 20-Day Moving Average | 60.89 |
| 10-Day Moving Average | 60.99 |
| Average True Range | 2.95 |
| RSI (14) | 35.48 |
| ADX | 26.08 |
| +DI | 20.04 |
| -DI | 33.44 |
| Chandelier Exit (Long, 3 ATRs) | 61.40 |
| Chandelier Exit (Short, 3 ATRs) | 61.49 |
| Upper Bollinger Bands | 69.53 |
| Lower Bollinger Band | 52.24 |
| Percent B (%b) | 0.11 |
| BandWidth | 28.41 |
| MACD Line | -0.81 |
| MACD Signal Line | 0.61 |
| MACD Histogram | -1.4283 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 57.49 | ||||
| Resistance 3 (R3) | 57.36 | 56.11 | 56.93 | ||
| Resistance 2 (R2) | 56.11 | 55.26 | 56.18 | 56.74 | |
| Resistance 1 (R1) | 55.13 | 54.73 | 55.62 | 55.26 | 56.56 |
| Pivot Point | 53.88 | 53.88 | 54.13 | 53.95 | 53.88 |
| Support 1 (S1) | 52.90 | 53.03 | 53.39 | 53.03 | 51.72 |
| Support 2 (S2) | 51.65 | 52.50 | 51.72 | 51.54 | |
| Support 3 (S3) | 50.67 | 51.65 | 51.35 | ||
| Support 4 (S4) | 50.80 |
